Clinical trial
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multiple Dose-Ranging Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Solrikitug in Adult Participants With Asthma (RAINIER)
NCT06496607 is registered in ClinicalTrials.gov with Uniquity One (UNI) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized, Double-blind, Placebo-controlled, Multiple Dose-Ranging Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Solrikitug in Adult Participants With Asthma (RAINIER)
- Lead sponsor
- Uniquity One (UNI)
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- July 26, 2024
- Completion date
- October 26, 2026
- Enrollment
- 145 (actual)
- Sites
- 69
Conditions
As the registry lists them; a condition with its own page is linked.